SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, continues to make significant strides in the development of innovative therapies targeting disorders of the central nervous system. In a groundbreaking announcement today, SciSparc highlighted a pivotal milestone in its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY0), a biotechnology company dedicated to addressing major mental health challenges through novel psychedelic-derived therapeutics.
A New European Patent Application: Addressing Binge Behaviors
As part of this ongoing collaboration, Clearmind has submitted a European patent application under the European Patent Office for a groundbreaking combination therapy involving MEAI (a novel psychedelic molecule) and N-Acylethanolamines. This innovative therapy is aimed at addressing various binge behaviors, including alcohol consumption, overeating, tobacco use, compulsive shopping, and sexual conduct. This submission represents an important step in the joint efforts of SciSparc and Clearmind to develop advanced solutions for under-treated mental health issues.
This achievement builds on an impressive intellectual property portfolio, with Clearmind having filed 13 patents related to this collaboration across the United States and other global jurisdictions.
SciSparc’s Vision and Current Pipeline
SciSparc is at the forefront of developing therapies leveraging cannabinoid pharmaceuticals. With a dedicated team of senior executives and scientists, the Company is focused on creating impactful treatments for some of the most challenging disorders of the central nervous system. SciSparc’s current drug development pipeline includes:
- SCI-110: Targeting Tourette Syndrome, Alzheimer’s disease, and agitation.
- SCI-210: Focused on autism and status epilepticus.
Additionally, SciSparc owns a controlling interest in a subsidiary that specializes in the sale of hemp seed oil-based products on Amazon.com, further diversifying its portfolio and market reach.
SciSparc and Clearmind’s Collaborative Research: A Revolutionary Approach
The collaboration with Clearmind is centered around exploring the potential of combining psychedelic molecules with the N-acylethanolamines family, which includes Palmitoylethanolamide. This approach represents a novel paradigm in the treatment of binge behaviors and other mental health disorders, showcasing the potential of integrating cutting-edge science with innovative drug delivery methods.
Recent Market Performance
SciSparc’s recent market activity has been noteworthy, reflecting growing investor confidence. As of 3:33:53 PM EST, SciSparc shares were trading at $1.1279, a dramatic increase of 114.2857% (+0.6000). The day’s trading range spans $0.8601 to $1.7900, with a 52-week range of $0.1970 to $6.7800. Volume has surged to an impressive 186,146,939, significantly outpacing the average volume of 4,837,469.
Looking Ahead
SciSparc’s collaboration with Clearmind and its commitment to cannabinoid-based drug development underscore its position as a leader in the pharmaceutical industry. As the Company continues to push the boundaries of innovation, it remains well-positioned to address some of the most pressing challenges in mental health and central nervous system disorders.
Investors and stakeholders alike will be watching closely as SciSparc and Clearmind advance their shared mission of delivering transformative therapies to patients worldwide.
